Form 4: BioXcel Therapeutics CFO Granted Stock Options

BioXcel Therapeutics' Chief Financial Officer, Richard Steinhart, was granted options to purchase 270,000 shares of common stock.

Summary

• Richard Steinhart, the Chief Financial Officer of BioXcel Therapeutics, was granted stock options on January 7, 2025.
• The options allow him to purchase 270,000 shares of common stock at an exercise price of $0.4713 per share.
• These options vest in twelve equal monthly installments over a twelve-month period, contingent on his continued employment with the company.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The grant of stock options aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages continued employment and performance.

Risks

• The value of the options is dependent on the future performance of BioXcel Therapeutics' stock price.
• If the CFO leaves the company before the options fully vest, he may forfeit some or all of the options.

Future Outlook

The stock options will vest over the next 12 months, subject to the CFO's continued employment.

Industry Context

Stock option grants are a common form of compensation for executives in the biotechnology industry, aligning their interests with the company's long-term success.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• The vesting schedule of 12 months is typical for such grants.
• The exercise price is set at the market price at the time of the grant.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CFO to improve the company's performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Next Steps

• The stock options will vest monthly over the next 12 months.
• The CFO may exercise the options at any time after they vest and before the expiration date.

Key Dates

Keywords

stock options, BioXcel Therapeutics, Richard Steinhart, CFO, equity compensation, vesting